Kaletra

Kaletra is a medication used to treat HIV-1 infection. It is a combination of two active substances: lopinavir and ritonavir. Lopinavir works directly against the virus, while ritonavir acts as a booster, slowing down the breakdown of lopinavir by the liver. This combination helps to reduce the viral load in the blood to very low levels, slowing down the progression of the disease.

Kaletra is available in tablet form, with strengths of 200 mg lopinavir and 50 mg ritonavir, and 100 mg lopinavir and 25 mg ritonavir. It is also available as an oral solution, containing 80 mg lopinavir and 20 mg ritonavir per milliliter.

The medication is typically taken once or twice daily, depending on the patient’s condition. It is most effective when used in combination with other antiretroviral agents. Kaletra does not cure HIV infection or AIDS but can help manage the disease by reducing the risk of infections and diseases associated with AIDS.

It is essential to use Kaletra under the guidance of a healthcare professional, especially for patients with severe liver disease or those taking other medications that could interact with it. The European Medicines Agency has recommended Kaletra for marketing authorization due to its effectiveness and manageable side effects.

For more detailed information, refer to the package leaflet or consult your doctor or pharmacist.